A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Recruiting · NCT07570862 · Interventional (participants receive a specific treatment) · Lead sponsor: Fate Therapeutics
View the official record on ClinicalTrials.gov →Interventions studied
FT819
What this trial is about
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.
Who can take part
Age range
12 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥12 to ≤70 years
- Diagnosis of SLE per EULAR/ACR 2019 classification criteria
- Biopsy-proven proliferative Class III or IV LN, with or without concomitant Class V involvement, based on the 2003/2018 ISN/RPS classification
- Positivity for at least one of the following autoantibodies at screening:
- Antinuclear antibody (ANA)
- Anti-double-stranded DNA (anti-dsDNA) or
- Anti-Smith antibody
- Active disease, defined as:
- a. Evidence of SLE activity, defined as either: i. SLEDAI-2K ≥6 or ii. At least 1 BILAG A or 2 BILAG B scores for SLE-related organ involvement; and b. Evidence of renal involvement, defined as UPCr ≥1 g/g; and c. Moderate-to-severe renal disease with investigator's impression that improvement is possible
- Refractory to ≥2 systemic immunosuppressive therapies for the treatment of LN
Exclusion criteria
- Evidence of inadequate organ function during the screening period
- Active central nervous system (CNS) symptoms attributable to autoimmune disease within 12 months prior to trial intervention
- History of or current renal diseases (other than LN) that, in the opinion of the investigator, could interfere with assessment of LN or confound evaluation of disease activity
- Receipt of dialysis (hemodialysis or peritoneal dialysis) within 12 weeks of trial intervention
- Irreversible organ damage related to underlying disease (e.g., ESRD) where, in the opinion of the investigator, CD19 CAR T-cell therapy would be unlikely to benefit the participant
- History of malignancy in the prior 5 years
- Known allergy to the following FT819 components: albumin (human) or DMSO
- History of intolerance or contraindication to bendamustine
- Body weight \<30 kg
- Any medical condition, clinical laboratory abnormality, or nonmedical/social issue that, per investigator or medical monitor judgement, precludes safe participation in and completion of the trial or that could affect compliance with protocol conduct or interpretation of results
Where it is running
9 locations listed across 5 US states.
- Wallace Rheumatic Studies Center - Beverly Hills, California, United States
- Kaiser Permanente Fontana - Fontana, California, United States
- Providence Medical Foundation - Fullerton, California, United States
- University of California San Francisco - San Francisco, California, United States
- GNP Research - Cooper City, Florida, United States
- Miami Dermatology and Laser Research - Miami, Florida, United States
- University of Nebraska Medical Center - Omaha, Nebraska, United States
- Cross Creek Medical Clinic - Fayetteville, North Carolina, United States
- The University of Texas Southwestern Medical Center - Dallas, Texas, United States